Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0802—Tripeptides with the first amino acid being neutral
  • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
  • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0815—Tripeptides with the first amino acid being basic
  • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1002—Tetrapeptides with the first amino acid being neutral
  • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
  • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1002—Tetrapeptides with the first amino acid being neutral
  • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
• • C—CHEMISTRY; METALLURGY
  • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
  • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
  • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
  • C11D3/16—Organic compounds
  • C11D3/38—Products with no well-defined composition, e.g. natural products
  • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
  • C11D3/38663—Stabilised liquid enzyme compositions
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
  • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
  • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
  • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
  • C12Y304/21—Serine endopeptidases (3.4.21)
  • C12Y304/21062—Subtilisin (3.4.21.62)
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to a liquid composition comprising a subtilisin and a peptide compound as a stabilizer for the subtilisin. It also relates to a peptide compound which is useful as a stabilizer for subtilisins.
• Subtilisin-type proteases are well known in liquid aqueous detergents, particularly for use on laundry washing.
• a generally encountered problem in such liquid detergents is the degradation by the subtilisin of other enzymes in the composition and of the subtilisin itself. Consequently, the stability of the subtilisin and other enzymes in the liquid detergent composition is reduced, resulting in a liquid detergent with a reduced wash performance.
• WO 94/04651 discloses the use of the peptide aldehydes Phe-Gly-Ala-PheH and Phe-Gly-Ala-LeuH for stabilizing subtilisin-type proteases.
• WO94/04651 also discloses Leu-Leu-TyrH as a suitable peptide aldehyde for stabilizing chymotrypsin-type proteases. Furthermore, WO94/04651 proposes methyl carbamate or methyl urea as an N-terminal protecting group of the peptide aldehydes.
• WO98/13460 discloses the use of peptide protease inhibitors, either peptide aldehydes or trifluromethyl ketones, where the peptide chain contains 2-5 amino acids and the aldehyde/ trifluromethyl ketone is derived from the amino acids alanine, valine, isoleucine, leucine, phenylglycine, phenylalanine or homophenylalanine and where the N-terminal protection group is preferably a sulphonamide or amidophoshate.
• WO2007/141736, WO2007/145963 and WO2007/145964 disclose the use of a reversible peptide protease inhibitor to stabilize liquid detergent compositions.
• US2003/157088 describes compositions containing enzymes stabilized with inhibitors.
• WO 96/41638 and WO 2005/105826 disclose peptide aldehydes and ketones.
• the invention provides a liquid composition comprising a subtilisin and a peptide compound of the formula B 2 -B 1 -B 0 -R wherein:
• R is hydrogen, CH 3 , CX 3, CHX 2 , or CH 2 X, wherein X is a halogen atom;
• B 1 is a single amino acid residue.
• B 0 may be a phenylalanine residue with an OH substituent at the p-position and/or at a m-position; and B 2 may consist of one or more amino acid residues, B 2 optionally comprising an N-terminal protection group.
• B 0 may be a single amino acid residue; and B 2 is a residue of GIy, Arg or Leu with an N-terminal protection group attached.
• the invention further provides a peptide compound of the formula B 2 -B 1 -B 0 -R wherein: • R is hydrogen, CH 3 , CX 3, CHX 2 , or CH 2 X, wherein X is a halogen atom; and
• B 1 is a single amino acid residue.
• B 0 may be a phenylalanine residue with an OH substituent at the p-position and/or at a m-position; and B 2 may consist of one or more amino acid residues with benzyloxycarbonyl as an N-terminal protection group, or B 2 may be a residue of GIy, Arg or Leu with an N- terminal protection group attached.
• B 0 may be a single amino acid residue, and B 1 may be a small amino acid residue, and B 2 may be a residue of GIy, Arg or Leu with an aromatic N-terminal protection group attached.
• amino acid residue indicates a group with a structure like -NH-CHR-CO- written with the N-terminal at the left and the C-terminal at the right.
• Amino acid residues are abbreviated using standard one-letter or three-letter abbreviations, including the following abbreviations: alanine (A), phenylalanine (F), glycine (G), leucine (L), arginine (R), valine (V), tryptophan (W), tyrosine (Y).
• Y-H denotes tyrosinal, meaning that the C-terminal end of the tyrosine residue is converted from a carbox- ylic group to an aldehyde group.
• the tyrosinal may be prepared by known processes.
• the amino acid may be an ⁇ -amino acid such as any of the naturally occurring amino acids, norvaline (Nva), norleucine (NIe), homo-phenylalanine (Hph) or phenyl-glycine (PgI)-
• the ⁇ -amino carbon atom may be in the D- or L-configuration.
• An OH-substituted phenylalanine such as tyrosine is a relatively hydrophilic amino acid, and its presence in a peptide will in general increase the solubility of the peptide compared to more hydrophobic amino acids like phenylalanine, leucine, alanine, cysteine, isoleu- cine, methionine and valine, which all have a positive hydropathy index compared to the negative hydropathy index of tyrosine (Kyte&Doolittle (1982), J. MoI. Biol. 157 (1 ), pp 105-132) (the larger hydropathy index is, the more hydrophibic amino acid).
• the peptide compound may have the formula:
• R is hydrogen, CH 3 , CX 3 , CHX 2 , or CH 2 X, wherein X is a halogen atom; X' is OH or H, at least one X' being OH; B 1 is a single amino acid residue; and B 2 is one or more amino acid residues, B 2 optionally comprising an N-terminal protection group.
• B 0 (the amino acid residue at the C-terminal) may be a residue of tyrosine (p- tyrosine), m-tyrosine or 3,4-dihydroxyphenylalanine.
• tyrosine residue the amino acid residue at the C-terminal
• the peptide compound has the following formula:
• the peptide compound comprises only 3 amino acid residues including the C-terminal residue.
• the synthesis will be more cost-effective and the compounds have proven to be highly efficient inhibitors of enzyme activity.
• the peptide compounds having only three amino acid residues are protected by an N-terminal protection group. Accordingly, in this aspect the invention relates to compounds wherein B 2 is a single amino acid residue comprising an N-terminal protection group.
• the peptide compound is an aldehyde comprising only 3 amino acid residues, where B 2 is selected among arginine, glycine and leucine comprising an N-terminal protection group.
• B 2 is preferably selected among arginine and glycine comprising an N-terminal protection group.
• the peptide compound comprises at least four amino acid residues.
• the peptide compounds having at least four amino acid residues are protected by an N-terminal protection group.
• the inven- tion relates to compounds wherein B 2 is at least two amino acid residues comprising an N- terminal protection group.
• B 2 comprises an N-terminal amino acid residue having a non-polar side chain.
• the second amino acid residue of B 2 counted from the at- tachment to B 1 , has a non-polar side chain.
• the peptide compound comprises four amino acid residues where the N-terminal amino acid residue having a non-polar side chain is selected among glycine, leucine, phenylalanine, tyrosine and tryptophan.
• the N-terminal amino acid residue further comprises an N-terminal protection group. It is preferred that B 1 is a small amino acid residue.
• B 1 is alanine or valine.
• the following are considered to be small amino acids: alanine, cysteine, glycine, proline, serine, threonine, valine, norvaline, norleucine.
• the peptide compound may be an aldehyde wherein R is hydrogen, B 1 is a single amino acid, preferably selected among small amino acids such as valine and alanine, B 2 comprises at least two amino acid residues and wherein at least one of said two amino acid residues is selected among phenylalanine, glycine and leucine, and wherein the second amino acid residue of B 2 has a non-polar side chain selected among phenylalanine, glycine, leucine, tyrosine and tryptophan.
• B 2 comprises an acetyl (Ac) N-terminal protection group, providing, inter alia, the peptide aldehyde compounds Ac-FGAY-H, Ac-LGAY-H, Ac- YGAY-H, Ac-FGVY-H and Ac-WLVY-H.
• the compounds according to this aspect of the invention comprise less than 10 amino acid residues, such as 9, 8, 7, 6, 5 or most preferably 4 amino acid residues.
• the peptide compound may be a tri-peptide aldehyde wherein R is hydrogen, B 1 is a single amino acid selected among small amino acids, e.g. valine and ala- nine, B 2 comprises an amino acid residue selected among arginine, glycine and leucine.
• B 2 comprises an N-terminal protection group selected among benzyloxycarbonyl (Z) and acetyl (Ac), providing, inter alia, the peptide aldehyde compounds Z-RAY-H, Z-GAY-H, Z- GAL-H, Z-GAF-H, Z-GAV-H, Z-RVY-H, Z-LVY-H and Ac-GAY-H.
• B 2 comprises an N-terminal amino acid residue having a non-polar side chain.
• amino acids with non-polar side chain is meant an amino acid or amino acid residue selected from the group comprising: phenylalanine, tyrosine, tryptophan, isoleucine, leucine, methionine, valine, alanine, proline, glycine, norvaline, or norleucine.
• Particularly preferred peptide aldehydes of the present invention include Z-RAY-H, Ac-GAY-H, Z-GAY-H, Z-GAL-H, Z-GAF-H, Z-GAV-H, Z-RVY-H, Z-LVY-H, Ac-LGAY-H, Ac- FGAY-H, Ac-YGAY-H, Ac-FGVY-H or Ac-WLVY-H, where Z is benzyloxycarbonyl and Ac is acetyl.
• the N-terminal protecting group may be any amino-terminal protecting group which can be employed in peptide synthesis.
• Gross and Meinhoffer, eds., The Peptides, Vol. 3; 3-88 (1981 ), Academic Press, New York 1981 discloses numerous suitable amine protecting groups and is incorporated herein by reference for that purpose.
• suitable groups include formyl, acetyl, benzoyl, trifluoroacetyl, fluorome- thoxy carbonyl, methoxysuccinyl, aromatic urethane protecting groups, such as, benzyloxycarbonyl; and aliphatic urethane protecting groups, such as t-butyloxycarbonyl or adamanty- loxycarbonyl, p-methoxybenzyl carbonyl (MOZ), benzyl (Bn), p-methoxybenzyl (PMB) or p- methoxyphenyl (PMP).
• aromatic urethane protecting groups such as, benzyloxycarbonyl
• aliphatic urethane protecting groups such as t-butyloxycarbonyl or adamanty- loxycarbonyl, p-methoxybenzyl carbonyl (MOZ), benzyl (Bn), p-methoxybenzyl (PMB) or p
• the N-terminal protection group of the present invention is selected among formyl, acetyl, benzoyl, aromatic or aliphatic urethanes, more preferably acetyl or benzyloxycarbonyl.
• the N- terminal protection group is preferably an aromatic or aliphatic urethane or an aromatic N- terminal protection group, particularly benzyloxycarbonyl (Cbz), p-methoxybenzyl carbonyl (MOZ), benzyl (Bn), p-methoxybenzyl (PMB) or p-methoxyphenyl (PMP), more preferably benzyloxycarbonyl.
• the N-terminal protection group is formyl, acetyl or benzoyl, more preferably acetyl.
• the peptide compounds of the present invention are used for stabilizing or inhibiting subtilisins in liquid compositions, which may further comprise a surfactant and other enzymes.
• the invention further relates to the use of a compound as defined above for stabilizing and/or inhibiting enzymes including a subtilisin-type protease.
• the enzymes are stabilized and/or inhibited in liquid detergents. Addition of the peptide compound to the liquid detergent may increase the detergency.
• the liquid composition may be an enzyme composition comprising a subtilisin and optionally a second enzyme.
• the second enzyme may be any commercially available enzyme, in particular an enzyme selected from the group consisting of proteases, amylases, lipases, cellu- lases, mannanases, oxidoreductases, lyases and any mixture thereof. Mixtures of enzymes from the same class (e.g. proteases) are also included.
• the enzyme composition may also include other stabilizers, e.g. a polyol such as glycerol or propylene glycol, e.g. in an amount of 25-75 % by weight.
• the amount of enzyme used in the liquid composition varies according to the type of enzyme(s) and the type of composition.
• the amount of each enzyme will typically be 0.04-80 micro-M, in particular 0.2-30 micro-M, especially 0.4-20 micro-M (generally 1-2000 mg/l, in particular 5-750 mg/l, especially 10-500 mg/l) calculated as pure enzyme protein.
• the amount of each enzyme will typically be 0.01-20 mM, in particular 0.04-10 mM, especially 0.1-5 mM (generally 0.3- 500 g/l, in particular 1-300 g/l, especially 3-150 g/l) calculated as pure enzyme protein.
• the enzymes are normally incorporated into detergent compositions at levels sufficient to provide an in-wash effect, which will be known to the skilled person in the art. Normally this would be in the range from 0.0001 % (w/w) to 5 % (w/w). Typical amounts are in the range from 0.01 % to 1 % by weight of the liquid detergent composition.
• the molar ratio of enzyme stabilizer or inhibitor according to the invention to protease is at least 1 :1 or 1.5:1 , and it is less than 1000:1 , more preferred less than 500:1 , even more preferred from 100:1 to 2:1 or from 20:1 to 2:1 , or most preferred, the molar ratio is from 10:1 to 3:1.
• the invention relates to a composition
• a composition comprising from 1 to 95% weight% of detersive surfactant(s), from 0.0001 to 5% by weight of a subtilisin, and from 0.00001 to 1 % weight% of a peptide inhibitor as defined above.
• the invention relates to a composition comprising from 2 to 60% by weight of detersive surfactant(s), from 0.0005 to 1 % by weight of a subtilisin, and from 0.00005 to 0.2% by weight of a peptide inhibitor as defined above.
• the invention relates to a composition
• a composition comprising from 3 to 50% by weight of detersive surfactant(s), from 0.001 to 0.5% by weight of a subtilisin, and from 0.0001 to 0.1% by weight of a peptide inhibi- tor as defined above.
• the subtilisin may be of animal, vegetable or microbial origin, including chemically or genetically modified mutants. It may be a serine protease, preferably an alkaline microbial protease. Examples are subtilisin-type proteases from the I-S group defined by Siezen et al. (Protein Engineering, 1991 , vol. 4 no. 7 pp. 719-737) Examples of subtilisins are those derived from Bacillus, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin BPN', subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279).
• proteases examples include KannaseTM,
• EverlaseTM EsperaseTM , AlcalaseTM , NeutraseTM, DurazymTM, SavinaseTM, OvozymeTM, Li- quanaseTM , PolarzymeTM, PyraseTM , Pancreatic Trypsin NOVO (PTN), Bio-FeedTM Pro and Clear-LensTM Pro (all available from Novozymes A/S, Bagsvaerd, Denmark).
• proteases include RonozymeTM Pro, MaxataseTM, MaxacalTM, MaxapemTM , OpticleanTM, ProperaseTM , PurafectTM, Purafect OxTM and Purafact PrimeTM (available from Genencor International Inc., Gist-Brocades, BASF, or DSM Nutritional Products).
• the liquid composition may comprise a second enzyme selected from the group consisting of amylases, lipases, cellulases, mannanases, oxidoreductases and lyases; particularly preferred is a liquid composition in which the second enzyme is a lipase.
• Suitable amylases include those of bacterial or fungal origin. Chemically or genetically modified mutants are included.
• Amylases include for example an alpha-amylase from B. licheniformis, described in GB 1 ,296,839.
• amylases are DuramylTM, TermamylTM , StainzymeTM, Stainzyme PlusTM, Termamyl UltraTM, FungamylTM and BANTM (available from Novozymes A/S) and RapidaseTM, Maxamyl PTM, Pu- rastar and Purastar OxAm (available from Gist-Brocades and Genencor Inc.).
• Suitable cellulases may be of bacterial or fungal origin. Chemically or genetically modified mutants are included. It may be a fungal cellulase from Humicola insolens (US 4,435,307) or from Trichoderma, e.g. T. reesei or T. viride. Examples of cellulases are described in EP 0 495 257. Commercially available cellulases include CarezymeTM, CeIIu- zymeTM, CellucleanTM, CelluclastTM, and EndolaseTM (available from Novozymes), Puradax, Puradax HA, and Puradax EG (available from Genencor). Suitable oxidoreductases include a peroxidase or an oxidase such as a laccase.
• the peroxidase may be of plant, bacterial or fungal origin.
• peroxidases derived from a strain of Coprinus, e.g., C. cinerius or C. macrorhizus, or from a strain of Bacillus, e.g., B. pumilus, particularly peroxidase according to WO 91/05858.
• Suitable laccases herein include those of bacterial or fungal origin. Examples are laccases from Trametes, e.g., T. villosa or T. versicolor, or from a strain of Coprinus, e.g., C. cinereus, or from a strain of Myceliophthora, e.g., M. thermophila.
• Suitable lipolytic enzymes include a lipase or cutinase of bacterial or fungal origin. Chemically or genetically modified mutants are included. Examples include a lipase from Thermomyces lanuginosus (Humicola lanuginosa) described in EP 258 068 and EP 305 216, a Rhizomucor miehei lipase, e.g., as described in EP 238 023, a Candida lipase, such as a C. antarctica lipase, e.g., the C.
• Thermomyces lanuginosus Harmomyces lanuginosus
• Rhizomucor miehei lipase e.g., as described in EP 238 023
• Candida lipase such as a C. antarctica lipase, e.g., the C.
• antarctica lipase A or B described in EP 214 761 a Fusarium oxysporum lipase (WO 98/26057), a Pseudomonas lipase such as a P. pseudoalcaligenes and P. alcaligenes lipase, e.g., as described in EP 218 272, a P. cepacia lipase, e.g., as described in EP 331 376, a P. stutzeri lipase, e.g., as disclosed in BP 1 ,372,034, a P. fluores- cens lipase, a Bacillus lipase, e.g., a B.
• subtilis lipase (Dartois et al., (1993), Biochemica et Biophysica acta 1 131 , 253-260), a B. stearothermophilus lipase (JP 64/744992), B. pumilus lipase (WO 91/16422), Penicillium camenbertii lipase (Yamaguchi et al., (1991 ), Gene 103, 61-67), the Geotrichum candidum lipase (Shimada, Y. et al., (1989), J. Biochem. 106, 383- 388), and various Rhizopus lipases such as a R.
• delemar lipase Hass, MJ et al., (1991 ), Gene 109, 1 17-1 13
• a R. niveus lipase Kugimiya et al., (1992), Biosci. Biotech. Bio-chem. 56, 716-719
• a R. oryzae lipase Additional examples are cutinase from Pseudomonas mendocina (WO 88/09367), cutinase from Fusarium solani pisi (WO 90/09446) and cutinase from Humicola insolens (WO 2001/092502).
• the lipolytic enzyme may be a lipase variant, e.g. described in WO 2000/060063.
• lipases examples include LipexTM. LipoprimeTM, LipopanTM. Lipopan FTM. Lipopan XtraTM. LipolaseTM , LipolaseTM Ultra, LipozymeTM , PalataseTM , Resi- naseTM. NovozymTM 435 and LecitaseTM (all available from Novozymes A/S).
• Other commer- cially available lipases include LumafastTM (Pseudomonas mendocina lipase from Genencor International Inc.); LipomaxTM (Ps. pseudoalcaligenes lipase from Gist- Brocades/Genencor Int. Inc.); and Bacillus sp. lipase from Solvay enzymes. Further lipases are available from other suppliers such as Lipase P "Amano" (Amano Pharmaceutical Co. Ltd.).
• Suitable mannanases include those of bacterial or fungal origin. Chemically or genet- ically modified mutants are included. Examples of commercially available mannanases include MannawayTM (product of Novozymes) and MannaStar (product of Genencor).
• Suitable lyases include those of bacterial or fungal origin. Chemically or genetically modified mutants are included. Examples of lyases include a pectate lyase and a pectin lyase. Examples of commercially available lyases are PectawashTM and PectawayTM (prod- ucts of Novozymes).
• Example 1 Various peptide aldehydes were produced by a custom peptide synthesis company, all with a purity >80%. The peptide aldehydes were dissolved in DMSO to a concentration of 10 mg/ml before use.
• a model liquid detergent was prepared for testing the various stabilizers: Detergent base:
• Detergent A A reference detergent with enzymes was prepared: Detergent A:
• the detergents were placed in closed glasses at 35°C and 40 0 C. Residual activity of lipase and protease was measured (by comparison to a reference stored at -18°C) at different times, using standard enzyme analytical methods (protease measured by hydrolysis of N, N- dimethylcasein at 40 0 C, pH 8.3 and lipase measured by hydrolysis of p-nitrophenyl valerate at 40 0 C, pH 7.7). In the table below, 3x denotes 3 molar surplus of the inhibitor compared to the protease etc.
• Detergent L The following reference detergent with enzymes was prepared: Detergent L:
• detergent with stabilizer according to the invention was prepared and normalized to 100g of detergent:
• tyrosinal peptide aldehyde significantly improves the storage stability of the protease, lipase and amylase in a liquid detergent.
• Peptide aldehydes Z-GAF-H, Z-GAL-H and Z-GAY-H were produced by peptide synthesis, all with a purity >80%.
• the peptide aldehydes were dissolved in DMSO to a concentration of 10 mg/ml before use.
• De-ionized water Ad 99% pH adjusted to 8.0 with NaOH
• the detergents were placed in closed glasses at 40 0 C. Residual activity of protease was measured (by comparison to a reference stored at -18°C) after 1 week, using standard enzyme analytical methods (protease measured by hydrolysis of N,N-dimethylcasein at 40 0 C, pH 8.3).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Detergent Compositions (AREA)
• Peptides Or Proteins (AREA)
• Enzymes And Modification Thereof (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39671331

Family Applications (1)

Country Status (10)

Cited By (171)

Families Citing this family (3)

Family Cites Families (59)

• 2009
  • 2009-03-26 PL PL09724752T patent/PL2271660T3/pl unknown
  • 2009-03-26 MX MX2010010348A patent/MX2010010348A/es active IP Right Grant
  • 2009-03-26 EP EP20172820.1A patent/EP3725797A1/en active Pending
  • 2009-03-26 RU RU2010143597/04A patent/RU2510662C2/ru active
  • 2009-03-26 CN CN201610983448.9A patent/CN107090014B/zh active Active
  • 2009-03-26 WO PCT/EP2009/053580 patent/WO2009118375A2/en not_active Ceased
  • 2009-03-26 EP EP09724752.2A patent/EP2271660B1/en active Active
  • 2009-03-26 JP JP2011501232A patent/JP5973166B2/ja active Active
  • 2009-03-26 CN CN200980110696.0A patent/CN101981049B/zh active Active
  • 2009-03-26 BR BRPI0909084-3A patent/BRPI0909084B1/pt active IP Right Grant
  • 2009-03-26 US US12/933,895 patent/US9181296B2/en active Active
  • 2009-03-26 ES ES09724752T patent/ES2807603T3/es active Active
• 2013
  • 2013-12-19 RU RU2013156600A patent/RU2668563C2/ru active
• 2015
  • 2015-05-07 JP JP2015094574A patent/JP2015180736A/ja active Pending
• 2018
  • 2018-08-30 RU RU2018131246A patent/RU2018131246A/ru unknown

Also Published As

Similar Documents

Legal Events